Compare TransMedics Group Inc (TMDX) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Wynn Resorts, Limited — how do they compare? TransMedics Group Inc trades at $86.4 (market cap $3.00B), while Wynn Resorts, Limited trades at $90.11 (market cap $9.29B). The key difference: Wynn Resorts, Limited is far larger — about 3.1× TransMedics Group Inc's market cap, and Wynn Resorts, Limited pays a 1.11% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| TMDX | WYNN | |
|---|---|---|
Market Cap | $3.00B | $9.29B |
Sector | Technology | Consumer Cyclical |
52-Week High | $150.42 | $133.34 |
52-Week Low | $61.99 | $90.23 |
Enterprise Value | $3.39B | $19.53B |
Dividend Yield | — | 1.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Wynn Resorts (WYNN) trades at $92.22, up 0.74% today, with a bearish technical signal and mixed earnings. Q2 2026 EPS beat estimates at $1.24, but Q4 2025 and Q1 2026 missed. Revenue reached $7.14B in 2025, with net income margin at 6.06%. Recent news highlights Macau strength offset by U.S. margin pressure and rising capital expenditures for new projects.
Outlook: Analyst consensus is bullish with a $132.44 price target, but risks include high debt ($10.5B long-term), profit margin compression, and significant capital spending. The stock offers growth potential from Macau recovery and new developments, yet faces headwinds from operational costs and leverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
